Literature DB >> 1691358

Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity.

P J Henry1, J D Horowitz, W J Louis.   

Abstract

In the current study, the vasodilator and tolerance-inducing actions of a recently developed organic nitrate vasodilator, nicorandil, were compared to nitroglycerin (NTG) in an isolated coronary artery preparation. The order of potency for relaxing U46619-constricted bovine-isolated coronary artery rings was NTG greater than isosorbide dinitrate (ISDN) greater than nicorandil. NTG was approximately 250-fold more potent than nicorandil (mean EC50 values for relaxation; 0.044 and 11.2 microM, respectively; n = 6-8). Coronary artery rings preexposed for 60 min to NTG (30 microM) were subsequently markedly less responsive to the relaxant effects of NTG (7.5-fold increase in mean EC50 value, 68.4% decrease in Emax; p less than 0.001) and ISDN (14.1-fold increase in mean EC50 value; p less than 0.001), although only marginally less responsive to nicorandil (1.75-fold increase in mean EC50 value; p less than 0.05). Thus, the coronary artery relaxant actions of nicorandil were significantly less affected by NTG-induced tolerance than were the relaxant actions of the related organic nitrate compounds, NTG and ISDN. To compare the tolerance-inducing actions of NTG and nicorandil, the relaxant actions of a series of nitric oxide (NO)-containing vasodilators were determined in control coronary artery rings and in rings preexposed for 60 min to either 30 microM NTG or 5,000 microM nicorandil. Quantitatively, similar changes in coronary artery ring responsiveness were produced by tolerance induced by NTG and nicorandil; marked attenuation of responsiveness to NTG and to the nonnitrate compound 3-morpholinosydnonimine (SIN-1), but only marginal attenuation of responsiveness to nicorandil and NO.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691358     DOI: 10.1097/00005344-199003000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite.

Authors:  Abdul R Maher; Sayqa Arif; Melanie Madhani; Khalid Abozguia; Ibrar Ahmed; Bernadette O Fernandez; Martin Feelisch; A G O'Sullivan; Arthur Christopoulos; Aaron L Sverdlov; Doan Ngo; Rustem Dautov; Philip E James; John D Horowitz; Michael P Frenneaux
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

2.  Pharmacokinetics of nicorandil in patients with normal and impaired renal function.

Authors:  M Molinaro; G Villa; M B Regazzi; A Salvadeo; S Segagni; R Rondanelli; E Sartirana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

4.  The dualistic mode of action of the vasodilator drug, nicorandil, differentiated by glibenclamide in 86Rb flux studies in rabbit isolated vascular smooth muscle.

Authors:  V A Kreye; T Lenz; U Theiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-01       Impact factor: 3.000

5.  Baroreflex resetting but no vascular tolerance in response to transdermal glyceryl trinitrate in conscious rabbits.

Authors:  A P Serone; J A Angus; C E Wright
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 6.  The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region.

Authors:  Kevin Cheng; Khaldoon Alhumood; Fayez El Shaer; Ranil De Silva
Journal:  Adv Ther       Date:  2020-12-22       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.